The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Titov K.S.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;
Peoples’ Friendship University of Russia named after Patrice Lumumba

Karseladze D.A.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin

Kuts I.N.

Peoples’ Friendship University of Russia named after Patrice Lumumba

Lebedev S.S.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;
Russian Medical Academy of Continuous Professional Education

Grekov D.N.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;
Russian Medical Academy of Continuous Professional Education

Lorie Z.V.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin

Controversial issues of neoadjuvant hormone therapy for early luminal HER2-negative breast cancer in postmenopausal patients

Authors:

Titov K.S., Karseladze D.A., Kuts I.N., Lebedev S.S., Grekov D.N., Lorie Z.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2025;14(5): 89‑93

DOI: 10.17116/onkolog20251405189

Read: 258 times

Buy for 300₽
Contact the author
Table of contents

CONTROVERSIAL ISSUES OF NEOADJUVANT HORMONE THERAPY FOR EARLY LUMINAL HER2-NEGATIVE BREAST CANCER IN POSTMENOPAUSAL PATIENTS
CONTROVERSIAL ISSUES OF NEOADJUVANT HORMONE THERAPY FOR EARLY LUMINAL HER2-NEGATIVE BREAST CANCER IN POSTMENOPAUSAL PATIENTS

To cite this article:

Titov KS, Karseladze DA, Kuts IN, Lebedev SS, Grekov DN, Lorie ZV. Controversial issues of neoadjuvant hormone therapy for early luminal HER2-negative breast cancer in postmenopausal patients. P.A. Herzen Journal of Oncology. 2025;14(5):89‑93. (In Russ.)
https://doi.org/10.17116/onkolog20251405189

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

Management of breast cancer remains one of the basic problem of the modern oncology. Many years past experience testifies that the prevalence of pure surgical treatment of breast cancer was unnecessary radical. The used methods caused crippling procedures leading to psychologically grave cosmetic flaws. At present more reasonable trends are emerging towards deescalating the role of the surgeon and escalating the contribution of chemotherapeutic, hormonal and radiation methods of treatment. The present review summarizes the modern data on neoadjuvant hormonal therapy of early breast cancer (BC) particularly of the estrogen positive and Her2-neu negative molecular subtypes. In the group of early breast cancer the patients with locally disseminated, adjusted to the breast and regional lymph nodes, without distant metastases were included. Individual peculiarities of different subclasses of hormonal agent are analyzed: antiestrogens as well as aromatase inhibitors. Successful combined use of the hormones with CDK4/6 inhibitors is discussed. The results of such therapy are exemplified by data of big randomized trials (MONALEESA, MonarchE, PALLAS, PENELOP B). Specific markers are needed for rational choose, application and monitoring of hormonal therapy enabling choosing optimal agent and assessing the effect of treatment. Traditional morphological methods are not too adequate for precise judgment of the pCR after hormonal therapy. A significant aid may provide Ki67 immunohistochemistry, especially comparing basic and post therapeutical levels of expression. The review analyzes also material on the method of risk stratification of the relapses and establishing the prognosis after hormonal therapy.

Keywords:

early breast cancer
luminal A-subtype
axillary lymph node dissection
hormonal therapy
aromatase inhibitors

Authors:

Titov K.S.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;
Peoples’ Friendship University of Russia named after Patrice Lumumba

Karseladze D.A.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin

Kuts I.N.

Peoples’ Friendship University of Russia named after Patrice Lumumba

Lebedev S.S.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;
Russian Medical Academy of Continuous Professional Education

Grekov D.N.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;
Russian Medical Academy of Continuous Professional Education

Lorie Z.V.

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin

Received:

05.12.2024

Accepted:

07.02.2025

Close metadata

References:

  1. Guo F, Kuo YF, Berenson AB. Breast cancer incidence by stage before and after change in screening guidelines. Am J Prev Med. 2019; 56:100-108.  https://doi.org/10.1016/j.amepre.2018.08.018
  2. Sung H, Ferlay J, Siegel RL, Laversann, I. Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.  https://doi.org/10.3322/caac.21660
  3. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Zlokachestvennye novoobrazovaniya v Rossii v 2020 godu (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2021. (In Russ.).
  4. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N. et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384:164-172.  https://doi.org/10.1016/S0140-6736(13)62422-8
  5. Schneeweiss A., Chia S., Hickish T., Harvey V., Eniu A., Hegg R et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA) Ann. Oncol. 2013;24:2278-2284. https://doi.org/10.1093/annonc/mdt182
  6. Ke Yu, Xu Chi, Feng Wang, Hua Wang, Identification of the new molecular subtypes related to inflammation in breast cancer Medicine (Baltimore) 2024; 103(19): e38146. https://doi.org/10.1097/MD.0000000000038146
  7. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105(Suppl 1):33-43.  https://doi.org/10.1007/s10549-007-9701-x
  8. Eggemann H, Bernreiter AL, Reinisch M, Loibl S, Taran FA, Costa SD, Ignatov A. Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. Br J Cancer. 2019;120(3):301-305.  https://https://doi.org/10.1038/s41416-018-0369-2
  9. Lee M, Piao J, Jeon MJ. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen. Med J. 2020;61(4):317-322.  https://doi.org/10.3349/ymj.2020.61.4.317
  10. Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541-1557. https:/doi.org/10.1093/annonc/mdz235
  11. Yamamoto Y, Goto-Yamaguchi L,Masako Takeno M, Mutsuko Yamamoto-Ibusuki M, Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer Chin Clin Oncol. 2020;9(3):30.  https://doi.org/10.21037/cco.2020.03.02
  12. Hurvitz S.A., Bardia A, Quiroga V, Park Y.H, Blancas I, José Luis Alonso-Romero J.L. et al. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study Lancet Oncol 2023; 24: 1029-41  https://doi.org/10.1016/S1470-2045(23)00268-1
  13. Jones V, Schroeder M.C, Roberson M. L, De Andrade J, Lizarraga I.M. Differential response to neoadjuvant endocrine therapy for Black/African American and White women in NCDB. Breast Cancer Res Treat. 2024;203(1):125-134.  https://doi.org/10.1007/s10549-023-07106-8
  14. van de Ven S, Smit V.T, Dekker T.J, Nortier J.V. R, Kroep J.R. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2011;37:422-30.  https://doi.org/10.1016/j.ctrv.2010.11.006
  15. Xi Jin, Yi-Zhou Jiang, Sheng Chen, Ke-Da Yu, Zhi-Ming Shao, Gen-Hong Di. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. Oncotarget. 2015;6:9600-11.  https://doi.org/10.18632/oncotarget.3292
  16. Ferraro E,Fornier M.N. Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy Ann Transl Med. 2020; 8(24): 1694. https://doi.org/10.21037/atm-20-5406
  17. Carpenter R, Doughty J.C, Cordiner C, Moss N, Gandhi A, Wilson C, et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat. 2014;144(3):569-576.  https://doi.org/10.1007/s10549-014-2835-8
  18. Burstein H.J, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541-1557. https:/doi.org/10.1093/annonc/mdz235
  19. Madigan L.I, Dinh P, Graham J.D. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines. Breast Cancer Res. 2020; 22: 77.  https://doi.org/10.1186/s13058-020-01314-6
  20. Fontein D.B, Charehbili A, Nortier J.W, Kranenbarg M,E, Kroep J.R, Putter H et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial. Eur J Cancer. 2014;50(13):2190-2200. https://doi.org/10.1016/j.ejca.2014.05.010
  21. Sirico M,Virga A, Conte B, Urbini M, Ulivi P, Gianni C, et al. Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspective Crit Rev Oncol Hematol 2023;181:103900. https://doi.org/10.1016/j.critrevonc.2022.103900
  22. Allevi G., Strina C., Andreis D., Zanoni V., Bazzola, L., Bonardi, S. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. Br. J. Cancer. 2013;108: 1587-1592. https://doi.org/10.1038/BJC.2013.151
  23. Pariser A.C., Sedghi T., Soulos P.R., Killelea B., Gross C.,P., Mougalian S.,S. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States. Breast Cancer Res Treat. 2019;178(2):419-426.  https://doi.org/10.1007/s10549-019-05397-4
  24. Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33-43.  https://doi.org/10.1016/S1470-2045(19)30786-7
  25. Johnston S, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Clinical Trial Lancet Oncol. 2023;24(1):77-90.  https://doi.org/10.1016/S1470-2045(22)00694-5
  26. Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim S, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021;39(14):1518-1530. https://doi.org/10.1200/JCO.20.03639
  27. Rao P, Tullai J, Aspesi P, Mapa F Cohran N Sigoillot F al. Characterization of cancer cell lines made senescent by exposure to ribociclib, doxorubicin, or TGFβ1, and identification of genes required for entry into senescence and sensecent cell survival..In: AACR Annual Meeting 10-15 April and 17-21 May 2021. Cancer Research. 2021; 81 (13_Supplement): 2025  https://doi.org/10.1158/1538-7445.AM2021-2025
  28. Peuker CA, Yaghobramzi S, Grunert C, Keilholz L,Gjerga E, Hennig S et al. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. Eur, J Cancer 2022;162: 45-55.  https://doi.org/10.1016/j.ejca.2021.11.025
  29. Hamilton E, Spring L, Fasching P, Franco S, DeBoer RH, Cortes J et al. Pooled analysis of post-progression treatments after first-line endocrine therapy in patients with HR+/HER2- advanced breast cancer in the MONALEESA-2, -3, and -7 studies. In: SanAntonio Breast Cancer Symposium, San Antonio,TX, 6-10 December 2023. Cancer Res. 2023; 83 (5_Supplement): P4-01-42.  https://doi.org/10.1158/1538-7445.SABCS22-P4-01-42
  30. Petroni G, Formenti SC, Chen-Kiang S, Galuzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol 2020; 20: 669-679.  https://doi.org/10.1038/s41577-020-0300-y
  31. Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018;28(11):911-925.  https://doi.org/10.1016/j.tcb.2018.07.002
  32. Hong T, Hogger AC, Wang D, Qi Pan, Gansel J, Engleitner Th, et al. CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response. Cell Death Discovery. 2024; 10: 453.  https://doi.org/10.1038/s41420-024-02218-6
  33. Baselga, J., Semiglazov, V., Van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J. et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630-7.  https://doi.org/10.1200/JCO.2008.18.8391
  34. Semiglazova T, Tsirlina E, Poltoratskii A., Bus’ko E, Semiglazov V., Artem;eva A, Ivanov S, Bershtein L, at al Melatonin and metformin in neoadjuvant hormonotherapy in locally advanced breast cancer. Voprosi Oncologii. 2018; 64(5):612-619. (In Russ.). https://doi.org/10.37469/0507-3758-2018-64-5-612-619
  35. Miller WR, Dixon, JM, Macfarlane L, Cameron D, T.J. Anderson T.A. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. European Journal of Cancer. 2003; 39 (4): 462-468.  https://doi.org/10.1016/s0959-8049(02)00600-7
  36. Inda MA, Blok EJ, Kuppen PJK, Charehbili A, den Biezen-Timmermans EC, van Brussel A et al. Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer. Mol Cancer Ther. 2019;19(2):680-89.  https://doi.org/10.1158/1535-7163.MCT-19-0318
  37. Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N et al. Changes in recurrence score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. ESMO Open. 2019;4(1): pe000476. https://doi.org/10.1136/esmoopen-2018-000476
  38. Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White RL et al. Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial. J Surg Oncol. 2017;115(8):917-923.  https://doi.org/10.1002/jso.24610
  39. Giridhar KV, Liu MC. Available and emerging molecular markers in the clinical management of breast cancer. Expert Rev Mol Diagn. 2019;19(10):919-28.  https://doi.org/10.1080/14737159.2019.1664901
  40. Goncalves R, Ma C, Luo J, Suman V, Ellis MJ. Use of Neoadjuvant Data to Design Adjuvant Endocrine Therapy Trials for Breast Cancer. Nat Rev Clin Oncol. 2012;9:223-9.  https://doi.org/10.1038/nrclinonc.2012.21
  41. Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar A.S et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. Comparative Study. J Natl Cancer Inst. 2008;100(19):1380-8.  https://doi.org/10.1093/jnci/djn309
  42. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R et al., Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31(2):203-209.  https://doi.org/10.1200/JCO.2012.43.4134
  43. Lerebours F, Pulido M, Fourme E, Debled M, Becette V, Bonnefoi H, et al. Predictive Factors of 5-Year Relapse-Free Survival in HR+/HER2- Breast Cancer Patients Treated With Neoadjuvant Endocrine Therapy: Pooled Analysis of Two Phase 2 Trials. Br J Cancer. 2020; 122:759-65.  https://doi.org/10.1038/s41416-020-0733-x
  44. Ellis MJ, Miller WR, Tao Y, Evans DB, Chaudri Ross HA, Miki Y, et al. Aromatase Expression and Outcomes in the P024 Neoadjuvant Endocrine Therapy Trial. Breast Cancer Res Treat. 2009;116:371-8.  https://doi.org/10.1007/s10549-008-0161-8
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.